I don't follow HGSI too closely. I had thought that Albuferon was not as efficacious as the PEG's just better dosing/compliance. Is this release misleading?
3:19AM Human Genome Sciences reports positive interim results of Phase 2b trial of Albuferon (HGSI) 11.51 : Co reports results at Week 12 following the completion of therapy in a Phase 2b clinical trial of Albuferon in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens. The interim results of the Phase 2b trial demonstrated that Albuferon provided at least comparable efficacy vs. Pegasys. The treatment group receiving Albuferon 900-mcg doses every two weeks achieved a 59% rate of sustained virologic response at 12 weeks following completion of therapy, vs. 54% for Pegasys administered once every week.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.